Arcturus Therapeutics Expands Operations Campus In San Diego, California
11/04/2014
Founded in 2013, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNAR, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense, and microRNA oligotherapeutics. The company owns Unlocked Nucleic Acid chemistry technology and patent portfolio enabling the targeting of any gene in the human genome.
"The Arcturus story began at the cutting edge Johnson and Johnson Innovation Center here in San Diego. Today, we are 'graduating' from the incubator space and moving into top-tier facilities that will enable us to execute our vision of bringing transformational life-saving RNA medicines to patients," said Joseph E. Payne, President/CEO of Arcturus Therapeutics, Inc. "We are expanding our work force and hiring key individuals to help us develop premier RNA medicines, such as our lead rare disease drug candidate, LUNAR-101, for treatment of transthyretin-mediated amyloidosis."
"San Diego is a city of innovation. Arcturus Therapeutics is an excellent example of the region's entrepreneurial spirit. Outstanding high-growth biotechnology companies like Arcturus are making us a global leader in technological breakthroughs while also providing high quality jobs for San Diegans here at home," said San Diego Mayor Kevin Faulconer.
Project Announcements
Swiss-Based Stadler Expands Salt Lake City, Utah, Operations
09/15/2025
South Korea-Based PPI America Plans Iron County, Utah, Manufacturing Operations
09/15/2025
Apozeal Pharmaceuticals Expands Bucks County, Pennsylvania, Drug Manufacturing Operations
09/14/2025
Georgia-Pacific Expands Monroe County, Alabama, Cellulose Mill Operations
09/14/2025
Noble Plastics Expands St. Landry Parish, Louisiana, Production Operations
09/14/2025
Systems Planning & Analysis Expands Alexandria-Fairfax County, Virginia, Operations
09/13/2025
Most Read
-
Tariffs, Talent, and U.S. Expansion
Q3 2025
-
What We’re Getting Wrong About Gen Z’s Future in the Skilled Trades
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
A New Course for U.S. Shipbuilding
Q3 2025
-
Optimizing Your Rail-Served Transportation Network: Strategy Before Steel
Q2 2025